Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
uniQure N.V
QURE | US
17.58
USD0.77
4.58%
QURE | US
Loading StockChartView...
About uniQure N.V
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
17.58
Open
17.05
High
17.89
Low
17.02
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130 a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162 which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191 which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240 which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam the Netherlands.
View LessQURE | US
Risk
94.9
Sharpe
0.28
Luna's Score
45/100
Recommendation
Sell
Luna says (QURE | US)
What's Working
Strength based on increasing price with high volume
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
108.0%1 month
94.9%3 months
159.1%6 months
145.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
27.93
Price to book
3.22
Debt to equity
5.50
Debt to assets
0.73
Ent. to EBITDA
0.99
Ent. to rev.
0.21
PEG
-
Other Fundamentals
EBITDA
-217.12M
MarketCap
856.10M
MarketCap(USD)
856.10M
Div. yield
-
Op. margin
-425.99
Erngs. growth
-18.20
Rev. growth
359.40
Ret. on equity
-126.41
Short ratio
11.03
Short perc.
10.91
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
4.99
Range1M
4.99
Range3M
19.75
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.07
Price X volume
32.38M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.99 | 0.53 | Expensive |
| Ent. to Revenue | 0.21 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.22 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 159.05 | 72.80 | Riskier |
| Debt to Equity | 5.50 | -1.23 | Expensive |
| Debt to Assets | 0.73 | 0.25 | Expensive |
| Market Cap | 856.10M | 3.66B | Emerging |
